Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Clinical Data
So what: The stock has been on a tear over the past two weeks since the Food and Drug Administration approved its drug Viibryd for treating major depressive disorder.
Now what: Viibryd still has a ways to go before joining the ranks of other SSRIs such as Pfizer's Zoloft, Forest Labs' Lexapro, or GlaxoSmithKline's Paxil -- one Forbes reporter covered the opinions of a few doctors who are skeptical of Viibryd's supposed advantages. But for now, approval is a big step for Clinical Data.
Interested in any of these stocks? Add them to My Watchlist:
You can follow Ilan Moscovitz on Twitter @TMFDada. At the time of publication, Ilan didn't own shares of any company mentioned. Pfizer is a Motley Fool Inside Value selection. GlaxoSmithKline is a Motley Fool Global Gains recommendation. The Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.